Wildtype

Nature has perfected biochemical innovation over billions of years. Microbiome-Integrated Drug Discovery (MIDD) from the Wildtype harnesses this evolutionary intelligence by exploring natural microbial ecosystems—untouched and unmodified—to uncover novel metabolites, optimize drug interactions, and drive precision medicine

Sailing at the Intersection of Science and Discovery

WILDTYPE is a 42 ft sailboat with a research lab on a mission to uncover novel cures from the ocean’s microbiome. WILDTYPE is ready to embark on expeditions across diverse marine environments, from the coastal waters of New York to the hydrothermal vents of Iceland.

Our goal is to harness the power of nature, seeking groundbreaking solutions for human health. By studying unique microbial communities in extreme environments, we aim to discover novel antioxidants, antibiotics, and bioactive compounds with therapeutic potential.

Join us as we navigate the frontier of science—where evolution meets innovation, and the next medical breakthrough may be found beneath the waves.

Our Platform

Microbiome-Integrated Drug Discovery (MIDD): Unlocking the Next Frontier in Precision Medicine

From the wildtype to the clinic, MIDD is revolutionizing medicine by learning from the source: life itself.

Welcome to the Future of Drug Discovery

At the Genomic Observatory, we are pioneering Microbiome-Integrated Drug Discovery (MIDD)—an innovative approach that leverages cutting-edge AI, lab-on-a-chip technology, multi-omics profiling, and microbial metabolite screening to revolutionize drug development.

Why the Microbiome Matters in Drug Discovery

The human microbiome plays a crucial role in drug metabolism, efficacy, toxicity, and patient variability, yet conventional drug development pipelines largely overlook this factor. MIDD addresses this gap by integrating microbiome science into drug discovery, ensuring safer and more effective treatments.

Key Challenges in Drug Development

Microbiota-Drug Interactions Affect Efficacy::

Many drugs are metabolized by gut bacteria before reaching their target, altering their effectiveness.

Microbiome-Influenced Drug Toxicity:

Microbial metabolites can detoxify or enhance drug toxicity, leading to adverse effects.

Interindividual Variability:

Differences in gut microbiota explain why some patients respond well to a drug while others do not.

Our Innovative Approach

We utilize:

AI-Driven Microbiome Modeling:

Predicts drug-microbiome interactions for better drug design.

Lab-on-a-Chip Microfluidics:

Simulates the human gut microbiome for real-time drug testing

Multi-Omics Profiling:

Integrates genomics, transcriptomics, metabolomics, and proteomics for comprehensive insights.

Microbial Metabolite Screening:

Identifies microbiome-derived compounds that influence drug metabolism and therapeutic effects.

Impact on Drug Development

Improved Drug Efficacy & Safety:

Reduces trial failures by identifying microbiome-based risks early.

Faster, Cost-Effective Drug Discovery:

Minimizes reliance on traditional animal models, streamlining clinical trials.

Precision Medicine Advancements:

Enables microbiome-based patient stratification for tailored therapies.